FDA Warning Letter · #721450
Kin Meds — FDA Warning Letter (February 20, 2026)
Primary Source
View the original FDA letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kin-meds-721450-02202026
Summary
- Company
- Kin Meds
- Letter number
- #721450
- Issue date
- February 20, 2026
- Subject
- Compounded GLP-1 marketing and labeling concerns
What FDA cited
This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://kinmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C.
From the letter
Read full letter on FDA.gov →Quoted verbatim from the FDA warning letter dated February 20, 2026
Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs
Issuing Office: Center for Drug Evaluation and Research (CDER) United States
Source: U.S. Food and Drug Administration. Quoted as a verbatim excerpt for editorial commentary; no claim is made beyond what FDA itself has published. The full letter is available at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kin-meds-721450-02202026
What FDA warning letters mean
A warning letter is FDA's principal means of telling a company that the agency considers something it's doing — a marketing claim, a manufacturing practice, a labeling choice — to violate the Federal Food, Drug, and Cosmetic Act. Companies typically have 15 working days to respond.
A warning letter is not a recall, a criminal charge, or a finding that the company has broken the law. It is the start of a regulatory conversation. FDA may issue a close-out letter once it is satisfied that the company has corrected the cited issues.
For compounded GLP-1 telehealth providers, the most common citations involve unapproved new drug claims, misbranding, and the use of bulk drug substances not on FDA's approved list under FDCA sections 503A and 503B.
Other warning letters in our database
- Novo Nordisk Inc. — March 5, 2026
- Join Josie — February 20, 2026
- FitRx — February 20, 2026
- Measured — February 20, 2026
- Refills Health — February 20, 2026
Editorial Disclaimer
FDA warning letters are public regulatory communications and do not, on their own, indicate that a company has done anything illegal. Companies often respond to warning letters with corrective action, and many letters are eventually closed out. The full text of this letter is available on fda.gov via the link above.